Stifel Maintains Buy on Globus Medical, Raises Price Target to $70
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Mathew Blackman has maintained a Buy rating on Globus Medical (NYSE:GMED) and increased the price target from $64 to $70, indicating a positive outlook on the company's stock.
May 08, 2024 | 1:21 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Stifel analyst Mathew Blackman reaffirmed a Buy rating on Globus Medical and raised the price target to $70 from $64.
The increase in price target by Stifel reflects a strong confidence in Globus Medical's future performance. Such analyst actions often lead to positive short-term price movements as they can influence investor sentiment and expectations.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100